Cargando…

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huemer, Florian, Melchardt, Thomas, Jansko, Bettina, Wahida, Adam, Jilg, Stefanie, Jost, Philipp J., Klieser, Eckhard, Steiger, Katja, Magnes, Teresa, Pleyer, Lisa, Greil‐Ressler, Sigrun, Rass, Christof, Greil, Richard, Egle, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849823/ https://www.ncbi.nlm.nih.gov/pubmed/30725494 http://dx.doi.org/10.1111/ejh.13218

Ejemplares similares

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations
por: Greil, Richard, et al.
Publicado: (2018)

Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
por: Leisch, Michael, et al.
Publicado: (2019)

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017
por: Magnes, Teresa, et al.
Publicado: (2017)

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
por: Magnes, Teresa, et al.
Publicado: (2017)

Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
por: Magnes, Teresa, et al.
Publicado: (2021)

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
por: Magnes, T., et al.
Publicado: (2021)

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
por: Schlick, Konstantin, et al.
Publicado: (2019)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
por: Leisch, Michael, et al.
Publicado: (2020)

How I treat diffuse large B-cell lymphoma
por: Melchardt, T., et al.
Publicado: (2023)

Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group
por: Jansko-Gadermeir, Bettina, et al.
Publicado: (2023)

S174: MYELOID NGS ANALYSES OF PAIRED SAMPLES FROM BONE MARROW AND PERIPHERAL BLOOD YIELD CONCORDANT RESULTS: A PROSPECTIVE COHORT ANALYSIS OF THE AGMT STUDY GROUP
por: Pleyer, Lisa, et al.
Publicado: (2023)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
por: Schlick, Konstantin, et al.
Publicado: (2018)

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome
por: MELCHARDT, THOMAS, et al.
Publicado: (2013)

A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc(™)) in patients with locally advanced or metastatic cancer
por: Greil, Richard, et al.
Publicado: (2018)

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation
por: Wolff, Florian, et al.
Publicado: (2017)

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer
por: Huemer, Florian, et al.
Publicado: (2015)

Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
por: Ji, Jiang, et al.
Publicado: (2020)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
por: Melchardt, Thomas, et al.
Publicado: (2014)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
por: Candoni, Anna, et al.
Publicado: (2022)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
por: Liu, Yifan, et al.
Publicado: (2023)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
por: Magnes, Teresa, et al.
Publicado: (2021)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
por: Lim, Byungho, et al.
Publicado: (2022)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
por: Vachhani, Pankit, et al.
Publicado: (2022)

NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
por: Prochazka, Katharina T, et al.
Publicado: (2016)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
por: Melchardt, Thomas, et al.
Publicado: (2015)

Digging deep into “dirty” drugs – modulation of the methylation machinery
por: Pleyer, Lisa, et al.
Publicado: (2015)

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE
por: Wang, Yuexi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bj0iu2e5rebcb0cgn1euc3sk9q